Inhaled drug shows promise for rare lung disease combination

A therapeutic principle rooted in decades of pulmonary vascular research is entering a new stage of clinical development. The investigational inhaled drug mosliciguat, a soluble guanylate cyclase (sGC) activator, has produced ...

Anti-epileptic drug may reduce migraine aura

A new study by researchers at Lund University in Sweden found that 85% of patients with aura-dominant migraine experienced a reduction in monthly aura days by at least half following treatment with the anti-epileptic drug ...

page 4 from 40